908. Outcomes Research: Myeloid Malignancies: Poster III

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

National analysis of real world racial and ethnic disparities in mortality complications and healthcare costs among adults hospitalized with newly diagnosed Acute Myeloid Leukemia

Impact of sociodemographic factors on survival outcomes in chronic myeloid leukemia in the United States A time trend analysis

Real world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis An analysis of the Medicare fee for service claims database

Socioeconomic inequalities and health related quality of life profile of patients with Myelodysplastic Syndromes MDS Analysis of 504 patients with higher risk MDS

The humanistic burden of patients with chronic myeloid leukemia CML treated with first line 1L tyrosine kinase inhibitors TKIs

Examining diet quality and patient reported outcomes in myeloproliferative neoplasms Results from a cross sectional observational study

Treatments and outcomes of adult patients with TP53 mutated acute myeloid leukemia AML in the real life –Report of the prospective french observational ALFA PPP study

Socioeconomic inequality in acute myeloid leukaemia treatment in England What drives this inequality

Differences in peripheral neuropathy reports by race informed by electronic patient reported outcomes ePROs deployed in multiple myeloma MM clinical practice

Spiritual wellness and quality of life in adult patients with newly diagnosed acute leukemia receiving initial therapy Patient reported outcomes PROs from a prospective observational study

Treatment selection and functional outcomes in treatment related acute myeloid leukemia tAML and AML with myelodysplasia related changes MRC A multicenter prospective cohort study

Poor survival and temporal trends in blastic plasmacytoid dendritic cell neoplasm A SEER 2000–2022 analysis

Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies A real world analysis

Social determinants of health shape treatment course and long term outcomes in patients with high risk myeloproliferative neoplasms

Balancing the treatment outcomes Survival and quality of life among older adults with AML

Social determinants of health and outcomes in patients with acute leukemia Interim results from a prospective single institution study

Respiratory syncytial virus RSV infection in adults with blood cancer An England wide population study

Real world use of venetoclax and hypomethylating agents HMA in blastic plasmacytoid dendritic cell neoplasm BPDCN A multi institutional case series

Malnutrition An underrecognized comorbidity in hematologic malignancies in a single institution review of nutrition referrals

Changing burden of Acute Myeloid Leukemia in the United States A 23 year national analysis

Treatment patterns and clinical outcomes in patients with lower risk Myelodysplastic Syndromes rreated with first line luspatercept Findings from a medical record review in France and Germany

High response rates and early treatment patterns with venetoclax and azacitidine from the prospective liven study Real world AML care in Canada